Therapeutic options for patients with lymphoma and liver dysfunction or failure during mechlorethamine shortage

References

• Cupp MJ, Higa GM. Doxorubicin dosage guidelines in a patient with hyperbilirubinemia of Gilbert's syndrome. Ann Pharmacother 1998;32:1026–1029.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Wolf RC, Pereira DL, et al. Therapeutic options in patients with lymphoma and severe liver dysfunction. Mayo Clin Proc 2004;79:169–175.
   PubMed Web of Science ®Google Scholar
• Siddik ZH. Mechanisms of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumour platinum-based drugs. In: Alison M, editor. The cancer handbook. New York: John Wiley & Sons, Ltd; 2005. Ch 84b.
   Google Scholar
• Lu H, Wang JJ, Chan KK, et al. Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6. Xenobiotica 2006;36:367–385.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Briones J, Bruguera M, et al. Hodgkin's disease presenting as a cholestatic febrile illness: incidence and main characteristics in a series of 421 patients. Ann Hematol 1996;72: 357–360.
   PubMed Web of Science ®Google Scholar
• Goodman LS, Wintrobe MM, Dameshek W, et al. Landmark article Sept. 21, 1946: Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. By Louis S. Goodman, Maxwell M. Wintrobe, William Dameshek, Morton J. Goodman, Alfred Gilman and Margaret T. McLennan. JAMA 1984;251:2255–2261.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Lishner M, Kitay-Cohen Y. The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine. Anticancer Drugs 2002;13:177–179.
   PubMed Web of Science ®Google Scholar
• Norfolk DR, Child JA. Pulsed high dose oral prednisolone in relapsed or refractory multiple myeloma. Hematol Oncol 1989;7: 61–68.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684–3688.
   PubMed Web of Science ®Google Scholar
• Braude S, Portmann B, Gimson AES, et al. Fulminant hepatic failure in non-Hodgkin's lymphoma. Postgrad Med J 1982;58:301–304.
   PubMed Web of Science ®Google Scholar
• Rowbotham D, Wendon J, Williams R. Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases. Gut 1998;42:576–580.
   PubMed Web of Science ®Google Scholar
• Salo J, Nomdedeu B, Bruguera M, et al. Acute liver failure due to non-Hodgkin's lymphoma. Am J Gastroenterol 1993;88:774–776.
   PubMed Web of Science ®Google Scholar
• Colby TV, LaBrecque DR. Lymphoreticular malignancy presenting as fulminant hepatic disease. Gastroenterology 1982;82:339–345.
   PubMed Web of Science ®Google Scholar
• Barta SK, Yahalom J, Shia J, et al. Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin's lymphoma. Clin Lymphoma Myeloma. 2006;7:77–82.
   PubMedGoogle Scholar
• Reau NS, Jensen DM. Vanishing bile duct syndrome. Clin Liver Dis 2008;12:203–217, x.
   PubMed Web of Science ®Google Scholar
• Dourakis SP, Tzemanakis E, Deutsch M, et al. Fulminant hepatic failure as a presenting paraneoplastic manifestation of Hodgkin's disease. Eur J Gastroenterol Hepatol 1999;11:1055–1058.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Maurer MJ, Ziesmer SC, et al. Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. Am J Hematol 2012;87:865–869.
   PubMed Web of Science ®Google Scholar
• Charbonneau B, Maurer MJ, Ansell SM, et al. Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study. Cytokine 2012;60:882–889.
   PubMed Web of Science ®Google Scholar
• Blay JY, Rossi JF, Wijdenes J, et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997;72:424–430.
   PubMed Web of Science ®Google Scholar
• Koren G, Beatty K, Seto A, et al. The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother 1992;26:363–371.
   PubMed Web of Science ®Google Scholar
• Bond WS. Clinical relevance of the effect of hepatic disease on drug disposition. Am J Hosp Pharm 1978;35:406–414.
   PubMedGoogle Scholar
• Blaschke TF. Protein binding and kinetics of drugs in liver diseases. Clin Pharmacokinet 1977;2:32–44.
   PubMed Web of Science ®Google Scholar
• Black M. Liver disease and drug therapy. Med Clin North Am 1974;58:1051–1057.
   PubMed Web of Science ®Google Scholar
• Donelli MG, Zucchetti M, Munzone E, et al. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 1998;34:33–46.
   PubMed Web of Science ®Google Scholar
• Doxorubicin hydrochloride for injection, USP [package insert]. New York: Pfizer; 2011.
   Google Scholar
• Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer 1974;33:19–27.
   PubMed Web of Science ®Google Scholar
• Floyd J, Mirza I, Sachs B, et al. Hepatotoxicity of chemotherapy. Semin Oncol 2006;33:50–67.
   PubMed Web of Science ®Google Scholar
• Superfin D, Iannucci AA, Davies AM. Commentary: oncologic drugs in patients with organ dysfunction: a summary. Oncologist 2007;12:1070–1083.
   PubMed Web of Science ®Google Scholar
• Desai ZR, Van den Berg HW, Bridges JM, et al. Can severe vincristine neurotoxicity be prevented?Cancer Chemother Pharmacol 1982;8:211–214.
   PubMed Web of Science ®Google Scholar
• Falkson G, Hunt M, Borden EC, et al. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs 1992;10:337–343.
   PubMed Web of Science ®Google Scholar
• Hirsch J. An anniversary for cancer chemotherapy. JAMA 2006;296:1518–1520.
   PubMed Web of Science ®Google Scholar
• Christakis P. The birth of chemotherapy at Yale. Bicentennial lecture series: Surgery Grand Round. Yale J Biol Med 2011;84:169–172.
   PubMedGoogle Scholar
• Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478–1484.
   PubMed Web of Science ®Google Scholar
• Current drug shortages: mustargen (mechlorethamine HCl) injection. [Updated 1/6/2012]. Available from: http://www.ashp.org
   Google Scholar
• Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park) 2005;19: 1057–1063.
   PubMed Web of Science ®Google Scholar
• Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000;18:2780–2787.
   PubMed Web of Science ®Google Scholar
• Teusink AC, Hall PD. Toxicities of gemcitabine in patients with severe hepatic dysfunction. Ann Pharmacother 2010;44:750–754.
   PubMed Web of Science ®Google Scholar
• Felici A, Di Segni S, Milella M, et al. Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function. Clin Pharmacokinet 2009;48:131–141.
   PubMed Web of Science ®Google Scholar
• Paschke R, Worst P, Brust J, et al. [Hepatotoxicity with etoposide-ifosfamide combination therapy]. Onkologie 1988;11:273–275.
   PubMed Web of Science ®Google Scholar
• Treanda (bendamustine hydrochloride) for injection, for intravenous infusion. Detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). Silver Spring, MD: US FDA; 2008.
   Google Scholar
• Adcetris [package insert]. Bothel, WA: Seattle Genetics, Inc.; 2011.
   Google Scholar
• Clinical pharmacology study of brentuximab vedotin (SGN-35); 2009. Available from: http://www.cancer.gov/clinicaltrials/search/view?cdrid = 661641&version = HealthProfessional&protocolsearchid = 7602874; NCT 01026415.
   Google Scholar
• Metzger ML, Billett A, Link MP. The impact of drug shortages on children with cancer–the example of mechlorethamine. N Engl J Med 2012;367:2461–2463.
   PubMed Web of Science ®Google Scholar
• Crump M., Kuruvilla J, Couban S, et al. Gemcitabine, dexamethasone, cisplatin (GDP) compared to dexamethasone, cytarabine, cisplatin (DHAP) chemotherapy prior to autologous stem cell transplantation for relapsed and refractory aggressive lymphomas: final results of the randomized phase III NCIC CTG Study LY12. Blood 2012;120(Suppl. 1): Abstract 745.
   Google Scholar